Legal status
Legal status
  • 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass360.461 g·mol−1
3D model (JSmol)
  • O=C(NC(C)(C)C1=CC=CC=C1)C2=NN(CCCCC#N)C3=C2C=CC=C3
  • InChI=1S/C22H24N4O/c1-22(2,17-11-5-3-6-12-17)24-21(27)20-18-13-7-8-14-19(18)26(25-20)16-10-4-9-15-23/h3,5-8,11-14H,4,9-10,16H2,1-2H3,(H,24,27)

CUMYL-4CN-BINACA (also known as CUMYL-CYBINACA or SGT-78) is an indazole-3-carboxamide based synthetic cannabinoid that has been sold online as a designer drug.[1][2][3][4][5][6] It is a potent agonist for cannabinoid receptors CB1 and CB2, with in vitro EC50 values of 0.58 nM and 6.12 nM, respectively.[7] In mice, CUMYL-4CN-BINACA produces hypothermic and pro-convulsant effects via the CB1 receptor,[7] and anecdotal reports suggest it has an active dose of around 0.1 mg in humans.[8]

CUMYL-4CN-BINACA is metabolized to produce cyanide, raising concerns about liver toxicity.[6] There is one reported case of hyperthermia, rhabdomyolysis, and kidney failure associated with its use.[9]

See also


  1. ^ "4-cyano CUMYL-BUTINACA". Cayman Chemical.
  2. ^ Yeter O (November 2017). "Identification of the Synthetic Cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in Plant Material and Quantification in Post-Mortem Blood Samples". Journal of Analytical Toxicology. 41 (9): 720–728. doi:10.1002/dta.2248. PMID 28977413.
  3. ^ Staeheli SN, Poetzsch M, Veloso VP, Bovens M, Bissig C, Steuer AE, Kraemer T (January 2018). "In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Drug Testing and Analysis. 10 (1): 148–157. doi:10.1002/dta.2298. PMID 28885775.
  4. ^ Bovens M, Bissig C, Staeheli SN, Poetzsch M, Pfeiffer B, Kraemer T (December 2017). "Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Forensic Science International. 281: 98–105. doi:10.1016/j.forsciint.2017.10.020. PMID 29125990.
  5. ^ Ölmez, Nevin Arıkan; Kapucu, Hicran; Altun, Neslihan Çallı; Eren, Bülent (January 2018). "Identification of the synthetic cannabinoid N-(2-phenyl-propan-2-yl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in a herbal mixture product". Forensic Toxicology. 36 (1): 192–199. doi:10.1007/s11419-017-0372-y. ISSN 1860-8965. S2CID 28058750.
  6. ^ a b Åstrand, Anna; Vikingsson, Svante; Lindstedt, Daniel; Thelander, Gunilla; Gréen, Henrik; Kronstrand, Robert; Wohlfarth, Ariane (2018). "Metabolism study for CUMYL-4CN-BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway". Drug Testing and Analysis. 10 (8): 1270–1279. doi:10.1002/dta.2373. ISSN 1942-7611. PMID 29577658.
  7. ^ a b Kevin, Richard; Anderson, Lyndsey; McGregor, Iain; Boyd, Rochelle; Manning, Jamie; Glass, Michelle; Connor, Mark; Banister, Samuel (2019). "CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist". Frontiers in Pharmacology. 10: 595. doi:10.3389/fphar.2019.00595. PMC 6549035. PMID 31191320.
  8. ^ "EMCDDA–Europol Joint Report on a new psychoactive substance: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide (CUMYL-4CN-BINACA)".
  9. ^ El Zahran, Tharwat (August 2018). "A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis". Clinical Toxicology. 57 (6): 421–422. doi:10.1080/15563650.2018.1534241. PMID 30442067. S2CID 53566116.